Antimicrobial resistance profiles of Enterobacter cloacae and Klebsiella aerogenes a tertiary hospital in Turkey: A five-years study Antimicrobial resistance of E.cloacae and K.aerogenes

Main Article Content

Meryem Colak
Nergis Asgin


Objective: Enterobacter cloacae and Klebsiella aerogenes species have multiple drug resistance and antibiotic resistance is a growing problem regarding to treating infections.

Objective: The aim of this study was to determine and evaluate the antimicrobial resistance profiles of E. cloacae and K. aerogenes isolated from various clinical samples in our laboratory, retrospectively.

Material and Methods: Totally 223 patients who applied to Karabuk University Training and Research Hospital microbiology laboratory between October2016-December2020 were included in this study. Conventional methods and automated systems were used for the identification and antibiotic susceptibilities of strains. Antibiotic susceptibility results were evaluated as per the European Committee on Antimicrobial Susceptibility Testing (EUCAST) guidelines.

Results: Total of 223 clinical samples (urine 68.6%, blood 12.6%, endotracheal aspirate 7.2%, wound 4.9%, sputum 3.6%, bronchoalveolar lavage fluid 2.7%, and ear fluid 0.4%) obtained from 223 patients; 119  (53%) females and 104 (47%)  females, were analysed. The identified species were E. cloacae (132 strains, 59.2%) and K. aerogenes (91 strains, 40.8%).  The Enterobacter cloacae and Klebsiella aerogenes positivity was detected as 30(13.4%) and 20(9.0%) in the samples. The highest resistance was found against cefixime at a rate of 60%; the lowest resistance was against amikacin, meropenem and imipenem ranged between 3% and 4% in both E. cloacae and K. aerogenes strains.

Conclusions: Amikacin, imipenem and meropenem were the most effective antibiotics against E. cloacae and K. aerogenes. We may prefer TMP-SMX and ciprofloxacin, as oral antibiotic agents in the treatment of E. cloacae/K. aerogenes infections. Amikacin, gentamicin and carbapenems may be the first choice for parenteral antibiotics therapy


Download data is not yet available.

Article Details

How to Cite
Colak, M., & Asgin, N. (2021). Antimicrobial resistance profiles of Enterobacter cloacae and Klebsiella aerogenes a tertiary hospital in Turkey: A five-years study. Medical Science and Discovery, 8(3), 161-166.
Research Article


1. Salimiyan Rizi K, Ghazvini K, Farsiani H. Clinical and pathogenesis overview of Enterobacter infections. Rev Clin Med. 2020;6(4):146-54.

2. Davin-Regli A, Lavigne JP, Pagès JM. Enterobacter spp.: update on taxonomy, clinical aspects, and emerging antimicrobial resistance. Clin Microbiol Rev. 2019;32(4): e00002-19.

3. Tindall BJ, Sutton G, Garrity GM. Enterobacter aerogenes Hormaeche and Edwards 1960 (Approved Lists 1980) and Klebsiella mobilis Bascomb et al. 1971 (Approved Lists 1980) share the same nomenclatural type (ATCC 13048) on the 4 Approved Lists and are homotypic synonyms, with consequences for the name Klebsiella mobilis Bascomb et al. 1971 (Approved Lists 1980.). Int J Syst Evol Microbiol. 2017;67:502–4.

4. Ramirez D, Giron M. Enterobacter Infections. In: StatPearls (Internet). Treasure Island (FL): StatPearls Publishing; 2020.

5. Malek A, McGlynn K, Taffner S, Fine L, Tesini B, Wang J, et al. Next-generation-sequencing-based hospital outbreak investigation yields insight into Klebsiella aerogenes population structure and determinants of carbapenem resistance and pathogenicity. Antimicrob Agents Chemother. 2019;63(6):e02577-18.

6. Eichenberger EM, Thaden JT. Epidemiology and mechanisms of resistance of extensively drug resistant Gram-negative bacteria. Antibiotics. 2019;8(2):37.

7. Davin-Regli A, Pagès JM. Enterobacter aerogenes and Enterobacter cloacae; versatile bacterial pathogens confronting antibiotic treatment. Front Microbiol. 2015;6:392.

8. De Florio L, Riva E, Giona A, Dedej E, Fogolari M, Cella E, et al. MALDI-TOF MS Identification and Clustering Applied to Enterobacter Species in Nosocomial Setting. Front Microbiol. 2018;14(9):1885.

9. Jin C, Zhang J, Wang Q, Chen H, Wang X, Zhang Y, et al. Molecular Characterization of Carbapenem-Resistant Enterobacter cloacae in 11 Chinese Cities. Front Microbiol. 2018;17(9):1597.

10. Noël A, Vastrade C, Dupont S, de Barsy M, Huang TD, Van Maerken T, et al. Nosocomial outbreak of extended-spectrum β-lactamase-producing Enterobacter cloacae among cardiothoracic surgical patients causes and consequences. J Hosp Infect. 2019;102(1):54-60.

11. EUCAST European Committee on Antimicrobial Susceptibility Testing. Breakpoint tables for interpretation of MICs and zone diameters. Version 6.0-10.1. Accessed 20 Feb 2021

12. Boucher HW, Talbot GH, Bradley JS, Edwards JE, Gilbert D, Rice LB, et al. Bad bugs, no drugs: No ESKAPE! An update from the infectious diseases society of America. Clin Infect Dis. 2009;48:1-12.

13. Nedjai S, Barguigua A, Djahmi N, Jamali L, Zerouali K, Dekhil M, et al. Prevalence and characterization of extended spectrum beta-lactamase-producing Enterobacter cloacae strains in Algeria. J Infect Dev Ctries. 2013;7:804-11.

14. Willemsen I, Oome S, Verhulst C, Pettersson A, Verduin K, Kluytmans J. Trends in extended spectrum beta-lactamase (ESBL) producing Enterobacteriaceae and ESBL genes in a Dutch teaching hospital, measured in 5 yearly point prevalence surveys (2010-2014). PLoS One. 2015;10:e0141765 .

15. Uzunović S, Ibrahimagić A, Bedenić B. Antibiotic resistance in Enterobacter cloacae strains with derepressed/partly derepressed/inducible AmpC and extended spectrum beta-lactamases in Zenica-Doboj Canton, Bosnia and Herzegovina. Med Glas (Zenica). 2018;15(1):37-45.

16. Cui L, Zhao J, Lu J. Molecular characteristics of extended spectrum β-lactamase and carbapenemase genes carried by carbapenem-resistant Enterobacter cloacae in a Chinese university hospital. Turk J Med Sci. 2015;45(6):1321-8.

17. Ghanavati R, Emaneini M, Kalantar-Neyestanaki D, Maraji AS, Dalvand M, Beigverdi R, et al. Clonal relation and antimicrobial resistance pattern of extended-spectrum β-lactamase- and AmpC β-lactamase-producing Enterobacter spp. isolated from different clinical samples in Tehran, Iran. Rev Soc Bras Med Trop. 2018;51(1):88-93.

18. Khajuria A, Praharaj AK, Kumar M, Grover N. Carbapenem resistance among Enterobacter species in a tertiary care hospital in central India. Chemother Res Pract. 2014;972646:1-6.

19. Yazici Y, Aydin F, Tosun I, Kaklikkaya N, Caylan R, Koksal I. Resistance Rates for Various Antibiotic of Enterobacter Strains Isolated From Clinical Specimens Turk Mikrobiyol Cem Derg. 2004;34:29-32.

20. Aksaray S, Dokuzoguz B, Guvener E, Yucesoy M, Yulug N, Kocagoz S, et al. Surveillance of antimicrobial resistance among gram-negative isolates from intensive care units in eight hospitals in Turkey. J Antimicrob Chemother. 2000;46(4):649.

21. Ozcan N, Yakut S, Genisel N, Atmaca S. Identification and antimicrobial susceptibilities of Enterobacter species isolated from clinical specimen in southeastern Turkey from 2015 to 2017. J Bacteriol Mycol. 2020;8(1):175‒8.

22. Cai Y, Chen C, Zhao M, Yu X, Lan K, Liao K, et al. High Prevalence of Metallo-β-Lactamase-Producing Enterobacter cloacae From Three Tertiary Hospitals in China. Front Microbiol. 2019;10:1610.

23. Kaleli I, Demir M, Maralcan M, Ozturk S. The evaluation of Enterobacter Antibiotic Susceptibility of Enterobacter Strains. ANKEM. 2001;15(1):140–4.

24. Wang S, Xiao S-Z, Gu F-F, Tang J, Guo X- K, Ni Y-X, et al. Antimicrobial susceptibility and molecular epidemiology of clinical Enterobacter cloacae bloodstream isolates in Shanghai, China. PLoS one. 2017;12(12):e0189713.

25. Boutarfi Z, Rebiahi SA, Morghad T, Perez Pulido R, Grande Burgos MJ, Mahdi F, et al. Biocide tolerance and antibiotic resistance of Enterobacter spp. isolated from an Algerian hospital environment. J Glob Antimicrob Resist. 2019;18:291-7.

26. Khosravi AD, Abasi Montazeri E, Ghorbani A, Parhizgari N. Bacterial urinary tract infection in renal transplant recipients and their antibiotic resistance pattern: A four-year study. Iran J Microbiol. 2014;6(2):74-78.

27. Demir T, Buyukguclu T. Evaluation of the in vitro activity of fosfomycin tromethamine against Gram-negative bacterial strains recovered from community- and hospital-acquired urinary tract infections in Turkey. Int J Infect Dis. 2013;17(11):e966-e970.

28. Fajfr M, Balik M, Cermakova E, Bostik P. Effective Treatment for Uncomplicated Urinary Tract Infections with Oral Fosfomycin, Single Center Four Year Retrospective Study. Antibiotics. 2020;9(8):511.

29. Gupta K, Hooton TM, Naber KG, Wullt B, Colgan R, Miller LG, et al. International clinical practice guidelines or the treatment of acute uncomplicated cystitis and pyelonephritis in women: a 2010 update by the Infectious Diseases Society of America and the European Society for Microbiology and Infectious Diseases. Clin Infect Dis. 2011;52(5):103-20.